Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019
Wedbush Presentation August 2019 in NYC
KOL Event in NYC July 2019
Jefferies Healthcare Conference Presentation – June 2019
ObsEva Investor Presentation – April 2019
ObsEva Short Report 2018
Press Releases
ObsEva announces new composition of its Executive Committee
press release
September 11, 2019
Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…
Read moreObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF
press release
September 3, 2019
Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out…
Read moreObsEva SA to Participate in Upcoming Investor Conferences
press release
August 30, 2019
Geneva, Switzerland and Boston, MA – August 30, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2019
May 8, 2019
ObsEva Annual General Meeting 2018
May 9, 2018
Upcoming Events
Stock Information
Latest Press Release
ObsEva announces new composition of its Executive Committee
Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…
Read moreInvestor Contact
Media Contact
Media Switzerland & Europe
Christophe Lamps
Dynamics Group
+41 79 476 26 87
Media United States
Marion Janic
RooneyPartners LLC
+1 212-223-4017
Contacts
Sign up for news
